Press Release: LivaNova to Announce Third-Quarter 2024 Results
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
LivaNova Upgraded to Outperform at Baird, Stock Rises
Baird Upgrades LivaNova(LIVN.US) to Buy Rating, Raises Target Price to $66
Baird analyst David Rescott upgrades $LivaNova(LIVN.US)$ to a buy rating, and adjusts the target price from $55 to $66.According to TipRanks data, the analyst has a success rate of 47.3% and a total
LivaNova: Strong Buy Rating on Robust Revenue and Earnings Growth Outlook
Insider Sale: Director Francesco Bianchi Sells 1,500 Shares of LivaNova PLC (LIVN)
LivaNova Announces CHRO Hebbelinck's Planned Departure and Benefits
Barclays Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $61
Barclays analyst Matt Miksic maintains $LivaNova(LIVN.US)$ with a hold rating, and maintains the target price at $61.According to TipRanks data, the analyst has a success rate of 62.2% and a total
LivaNova (LIVN) Gets a Hold From Barclays
LivaNova PLC (NASDAQ:LIVN) Shares Could Be 36% Below Their Intrinsic Value Estimate
LivaNova Rises Following Possible CMS Reimbursement Boost for Vagus Nerve Stimulation
Baird Maintains Neutral on LivaNova, Maintains $55 Price Target
Baird Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $55
Baird analyst David Rescott maintains $LivaNova(LIVN.US)$ with a hold rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 45.7% and a total
LivaNova Hold Rating Justified by US VNS Reimbursement Uncertainty and Italian Legal Challenges
Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up
LivaNova to Present at the Baird Global Healthcare Conference
Transcatheter Heart Valve Replacement Market Report 2024-2032 Featuring Edwards Lifescience, Abbott Laboratories, Medtronic, LIVANOVA, Boston Scientific, Artivion, MicroPort Scientific, Venus Medtech
Microelectronic Medical Implants Market Report 2024-2029, With Profiles of Leading Players, Including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro
LivaNova | 10-Q: Q2 2024 Earnings Report
Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$49.40?